- Delivering Pan India
Exemptia® (Adalimumab) Adalimumab 40 mg / 0.8 mL pre-filled syringe by Zydus Lifesciences. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Adalimumab 40 mg / 0.8 mL |
|---|---|
| Manufacturer | Zydus Lifesciences |
| Country | India |
| Pack size | Adalimumab 40 mg / 0.8 mL: 1 pre-filled syringe (as shown on the carton) |
| Storage | Refrigerate at 2°C to 8°C; do not freeze; protect from light. |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Exemptia® (Adalimumab) Adalimumab 40 mg / 0.8 mL Pre-filled Syringe — TNF Blocker Pre-filled Syringe for Subcutaneous Use: A Sourcing Guide for Hospitals and Pharmacies
Exemptia® is a brand of adalimumab 40 mg/0.8 mL single-dose pre-filled syringe marketed in India by Zydus Lifesciences (formerly Cadila Healthcare), a biosimilar-class adalimumab. According to the current US prescribing information for the reference product Humira, adalimumab is a tumor necrosis factor (TNF) blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Indications in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe adalimumab, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Exemptia® (adalimumab) Adalimumab 40 mg / 0.8 mL pre-filled syringe to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the immunosuppressant medicines category. Supply is in bulk/wholesale quantities only.
Exemptia contains adalimumab 40 mg in 0.8 mL of solution in a single-dose pre-filled syringe for subcutaneous use, supplied in the pack size listed below.
How it works, according to the label: The reference label describes adalimumab as a TNF blocker, a monoclonal antibody that binds tumor necrosis factor alpha and blocks its interaction with TNF receptors.
The current US prescribing information for HUMIRA® (adalimumab) injection (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Exemptia pack insert.
The reference label summarises its Clinical Studies by indication. In rheumatoid arthritis, the ARMADA study of adalimumab with methotrexate was published by Weinblatt et al. in Arthritis & Rheumatism in 2003. Evidence is cited for the reference product for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Adalimumab 40 mg / 0.8 mL | Single-dose pre-filled syringe | 1 pre-filled syringe (as shown on the carton) |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, rheumatology and gastroenterology department buyers and pharmacies that source biologic products. Adalimumab is prescribed and supervised by a physician, as described in the prescribing information.
The reference label carries a boxed warning for serious infections and malignancy. It lists infections, injection site reactions, headache and rash among the most common adverse reactions (over 10%). This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Exemptia carton. This is a refrigerated biologic; the US Humira label describes storage in a refrigerator at 2°C to 8°C in the original carton, protected from light, and not frozen. Keep out of reach of children.
Exemptia is marketed by Zydus Lifesciences. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Exemptia through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Exemptia available in India?
A.K. Pharma supplies Exemptia (adalimumab) Adalimumab 40 mg / 0.8 mL pre-filled syringe to hospitals and pharmacies in India. Contact us for current availability.
What does Exemptia contain?
Adalimumab, a TNF blocker, 40 mg in 0.8 mL as a single-dose pre-filled syringe.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Exemptia be stored?
Refrigerate at 2°C to 8°C in the original carton, protected from light; do not freeze.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
